News
Once-Monthly MariTide Shows Promising Weight Loss in Obesity and Type 2 Diabetes: Phase 2 Trial
MariTide is designed to combine the effects of glucagon-like peptide-1 (GLP-1) receptor activation with glucose-dependent insulinotropic polypeptide (GIP) receptor antagonism. This unique mechanism targets key metabolic pathways involved in appetite regulation, insulin sensitivity, and weight management.
In the race to make the most tolerable obesity drug, there seems to be no clear winner—at least not according to analysts ...
Amgen shares fell sharply on Monday afternoon after the company released results from a weight-loss trial that showed that ...
Full Phase 2 study results showed side effects that led people to stop treatment with MariTide, as well as weight loss ...
Eli Lilly, Novo Nordisk and Amgen release weight loss drug data as competition heats up in the market, while Abridge ...
Weight loss medications such as Ozempic, Wegovy and Mounjaro have become popular and now there’s a new GLP-1 drug, MariTide, being tested that could be competitive in the market.
While Amgen’s monthly obesity candidate MariTide helped patients lose significant amounts of weight in a phase 2 study, ...
Novo Nordisk (NVO), and Amgen (NASDAQ:AMGN) are scheduled to present major clinical trial readouts at the American Diabetes ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback